Pathogenica And Life Technologies EMEA Partner To Control Hospital Acquired Infections

GLASGOW, Scotland, September 19, 2012 /PRNewswire/ --

 

Companies to co-market Pathogenica's HAI BioDetection Kits

through exclusive agreement in Europe, the Middle East and Africa

Life Technologies (NASDAQ: LIFE) announced an exclusive agreement with   Pathogenica, Boston, Massachusetts,  to co-market and distribute for research use, the Pathogenica HAI (Hospital Acquired Infection) BioDetection Kit on the Ion Torrent PGM ^{[ TM ]} in Europe, the Middle East and Africa (EMEA).

     (Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO )   

Based on Pathogenica's DxSeq ^{[ TM ]} technologyand the Ion Torrent ^{[ TM ]} sequencing platform, the kit enables identification of pathogens with high accuracy, at high specific strain resolution and at a scale that could make hospital-wide testing practical.

"Hospital acquired infections are becoming an increasingly serious health risk for patients and present significant economic issues for hospitals," said Peter Silvester, President, Life Technologies EMEA.  "The combination of Pathogenica's technology with the Ion Torrent PGM ^{[ TM ]} will provide a solution that can help address this problem by enabling hospitals to quickly detect these types of infections with extreme accuracy."

Pathogenica's analysis software provides simple, concise output reports that indicate which species and strains are present and at what levels. These kits are not for use in the diagnosis of hospital patients.

Current methods for detecting causative organisms can take days for results or are limited to a few pathogens.  The Pathogenica/Life Technologies HAI solution quickly and cost-effectively identifies not only what species are present in a sample, but also provides high-resolution sequence data that includes strain identity and resistance genes, which is critical information for understanding and containing or preventing HAI outbreaks. Pathogenica's kit can detect more than 12 pathogenic bacteria and 15 resistance gene families in a single assay and up to 12 samples can be tested per sequencing run.  Dozens of samples can simultaneously be tested in one day with results in an impressive timeframe of less than 12 hours.

1 2 3 Next › Last »